Solabegron (code name GW-427,353) is a drug which acts as a selective agonist for the β3 adrenergic receptor. It is being developed for the treatment of overactive bladder and irritable bowel syndrome. It has been shown to produce visceral analgesia by receptor-mediated attenuation of afferent nociceptive signaling and by relaxing detrusor and visceral smooth muscle through Gs protein coupling that raises intracellular cAMP, reducing spontaneous contractions and sensory hypersensitivity. In vitro pharmacology demonstrates pronounced β3 versus β1 and β2 selectivity, while preclinical efficacy shows dose-dependent increases in bladder capacity and reductions in visceral pain responses. Clinical pharmacokinetic properties include oral absorption with a profile supporting once- or twice-daily dosing, primary hepatic metabolism with identifiable oxidative and conjugative pathways, and a plasma elimination half-life compatible with sustained receptor occupancy. Safety assessments in development have focused on cardiovascular selectivity, CYP interaction potential, and tolerability in target populations.
The synthetic and stability-related impurity profile for solabegron commonly includes related substances such as N-oxide and other oxidative metabolites, O-dealkylated and N-dealkylated products, hydroxy and deaminated derivatives, and trace ring-modified degradants; residual solvents and inorganic counterions are also controlled. Typical analytical specifications used during development set individual unidentified impurity reporting thresholds at 0.05 to 0.10% w/w, individual specified related compounds at up to 0.20% w/w depending on toxicity assessment, and total impurities not to exceed approximately 0.5% w/w for release material, with genotoxic impurities controlled to the default limits defined by ICH M7 or by compound-specific qualification. Routine control methods employ reversed-phase HPLC with UV detection for quantitation, LC-MS for identification of trace species, and NMR for structural confirmation of major related compounds. Stability studies monitor formation rates of each degradant under ICH conditions to define shelf-life and packaging requirements.
Solabegron is being developed as a selective β3 adrenergic receptor agonist for indications that include overactive bladder and irritable bowel syndrome, with the therapeutic rationale of increasing bladder capacity, reducing spontaneous detrusor contractions, and decreasing visceral pain signaling.
Mirabegron is an approved β3 adrenergic receptor agonist indicated for the treatment of overactive bladder; it works by relaxing detrusor smooth muscle via β3 receptor activation to increase bladder storage capacity and reduce urinary urgency and frequency.
Recent additions to overactive bladder pharmacotherapy include newer β3 agonists such as vibegron, which was approved in several regions in the late 2010s and early 2020s; clinical development continues for other agents and combination approaches, so prescribing choice depends on approval status in the relevant jurisdiction and individual patient factors.
No, Solifenacin is not a β3 agonist. It is an antimuscarinic agent that primarily antagonizes M3 muscarinic receptors to reduce bladder smooth muscle contraction and decrease urinary urgency and frequency.
